The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches - Jain, Natasha A.; Lu, Kit; Ito, Sawa; Muranski, Pawel; Hourigan, Christopher S.; Haggerty, Janice; Chokshi, Puja D.; Ramos, Catalina; Cho, Elena; Cook, Lisa; Childs, Richard; Battiwalla, Minoo; et al. (Cytotherapy (Oxford, England), 2014)
Keywords: Adolescent; Adult; Advanced Basic Science; Aged; antiviral cellular therapy; Child; CMV reactivation; Cost of Illness; Cytomegalovirus - genetics; Cytomegalovirus - pathogenicity; Cytomegalovirus Infections - economics; Cytomegalovirus Infections - pathology; Cytomegalovirus Infections - virology; economic cost; Female; Hematologic Neoplasms - mortality; Hematologic Neoplasms - pathology; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - economics; Humans; Male; Middle Aged; Other; pre-emptive therapy; Risk Factors; T-Lymphocytes - immunology; T-Lymphocytes - pathology; T-Lymphocytes - virology; Tissue Donors; Transplantation, Homologous - adverse effects; Transplantation, Homologous - economics; Virus Activation - genetics; economic cost; CMV reactivation; pre-emptive therapy; antiviral cellular therapy